

IN THE CLAIMS

1. (currently amended) A method for identifying a compound potentially useful for
~~capable of~~ treating a cardiovascular disorder or a thrombotic disorder, comprising:

a) combining a compound to be tested with a 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419 polypeptide under conditions suitable for binding of the test compound to the polypeptide; and

b) detecting binding of the test compound to the polypeptide ~~to thereby identify a compound which binds to the polypeptide,~~

whereby a test compound which binds to the polypeptide is identified as potentially useful for
~~thereby identifying a compound capable of~~ treating a cardiovascular disorder or a thrombotic disorder.

2. (original) The method of claim 1, wherein the compound is selected from the group consisting of a small molecule, a peptide or an antibody.

3. (original) The method of claim 1, wherein the polypeptide further comprises heterologous sequences.

4. (original) The method of claim 1, wherein the polypeptide is an isolated polypeptide, a membrane-bound form of an isolated polypeptide or a cell comprising the polypeptide.

5. (original) The method of claim 1, wherein the disorder is aberrant vascularization, atherosclerosis, thrombosis, coronary artery disease, hyperlipidemia, dyslipidemia, high blood pressure and heart failure.

6. (original) The method of claim 1, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of: a) a competition binding assay; b) an immunoassay; and c) a yeast two-hybrid assay.

7. (currently amended) A method for identifying a compound potentially useful for ~~capable of~~ treating a cardiovascular disorder or a thrombotic disorder, comprising:

a) combining a compound to be tested with a host cell expressing a 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419 polypeptide under conditions suitable for binding of the test compound to the polypeptide; and

b) detecting binding of the test compound to the polypeptide ~~to thereby identify a compound which binds to the polypeptide,~~
whereby a test compound which binds to the polypeptide is identified as potentially useful for
~~thereby identifying a compound capable of~~ treating a cardiovascular disorder or a thrombotic disorder.

8. (original) The method of claim 7, wherein the compound is selected for the group consisting of a small molecule, a peptide, an antibody or an antisense nucleic acid molecule.

9. (original) The method of claim 7, wherein the polypeptide further comprises heterologous sequences.

10. (original) The method of claim 7, wherein the disorder is aberrant vascularization, atherosclerosis, thrombosis, coronary artery disease, hyperlipidemia, dyslipidemia, high blood pressure and heart failure.

11. (original) The method of claim 7, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

a) a competition binding assay;

b) an immunoassay; and

c) a yeast two-hybrid assay.

12-20. (canceled)